Opiant Pharmaceuticals (OPNT) versus Strongbridge Biopharma PLC (SBBP) Head to Head Survey
Opiant Pharmaceuticals (NASDAQ: OPNT) and Strongbridge Biopharma PLC (NASDAQ:SBBP) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their valuation, earnings, profitability, dividends, analyst recommendations, risk and institutional ownership.
This table compares Opiant Pharmaceuticals and Strongbridge Biopharma PLC’s net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
|Strongbridge Biopharma PLC||N/A||-83.83%||-34.77%|
Institutional and Insider Ownership
63.7% of Strongbridge Biopharma PLC shares are owned by institutional investors. 63.8% of Opiant Pharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Opiant Pharmaceuticals has a beta of -0.97, suggesting that its share price is 197% less volatile than the S&P 500. Comparatively, Strongbridge Biopharma PLC has a beta of 2.71, suggesting that its share price is 171% more volatile than the S&P 500.
Valuation and Earnings
This table compares Opiant Pharmaceuticals and Strongbridge Biopharma PLC’s gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||EBITDA||Earnings Per Share||Price/Earnings Ratio|
|Opiant Pharmaceuticals||$14.97 million||4.87||$5.99 million||$2.54||14.15|
|Strongbridge Biopharma PLC||$1.53 million||143.19||-$39.43 million||($2.78)||-2.23|
Opiant Pharmaceuticals has higher revenue and earnings than Strongbridge Biopharma PLC. Strongbridge Biopharma PLC is trading at a lower price-to-earnings ratio than Opiant Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
This is a summary of recent ratings and recommmendations for Opiant Pharmaceuticals and Strongbridge Biopharma PLC, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
|Strongbridge Biopharma PLC||0||0||3||0||3.00|
Strongbridge Biopharma PLC has a consensus price target of $13.33, indicating a potential upside of 115.05%. Given Strongbridge Biopharma PLC’s higher probable upside, analysts plainly believe Strongbridge Biopharma PLC is more favorable than Opiant Pharmaceuticals.
Opiant Pharmaceuticals beats Strongbridge Biopharma PLC on 7 of the 12 factors compared between the two stocks.
Opiant Pharmaceuticals Company Profile
Opiant Pharmaceuticals, Inc., formerly Lightlake Therapeutics, Inc., is a specialty pharmaceutical company. The Company develops pharmacological treatments for substance use, addictive and eating disorders. The Company has developed NARCAN (naloxone hydrochloride) Nasal Spray, a treatment to reverse opioid overdoses, which was conceived, licensed, developed and approved by the United States Food and Drug Administration (FDA). The Company’s pipeline of product candidates includes a treatment for Binge Eating Disorder (BED), a treatment for Bulimia Nervosa (BN), a treatment for Cocaine Use Disorder (CocUD) and a heroin vaccine. The Company also is focused on other treatment opportunities.
Strongbridge Biopharma PLC Company Profile
Strongbridge Biopharma plc is a global commercial-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies for a range of diseases. The Company’s commercial product, KEVEYIS (dichlorphenamide), is indicated for the treatment of hyperkalemic, hypokalemic and related variants of primary periodic paralysis. The United States Food and Drug Administration (FDA) has granted orphan drug designation for KEVEYIS. The Company has a clinical-stage pipeline of therapies for endocrine diseases. The Company’s lead compounds include COR-003 (levoketoconazole), a cortisol synthesis inhibitor, and COR-005 (veldoreotide), a somatostatin analog (SSA). The Company is studying COR-003 for the treatment of endogenous Cushing’s syndrome. It is investigating COR-005 for the treatment of acromegaly. Both COR-003 and COR-005 have received orphan designation from the FDA and the European Medicines Agency (EMA).
Receive News & Ratings for Opiant Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.